·189·《实用器官移植电子杂志》 2021年5月第9卷第3期 Prac J Organ Transplant(Electronic Version), May 2021,Vol.9,No.3
lymphoproliferative disease in pediatric patient[J]. PET Clin,
2020,15(3):309-319.
[15]GRULICH A E,VAN LEEUWEN M T,FALSTER M O,et al.
Incidence of cancers in people with HIV/AIDS compared with
immunosuppressed transplant recipients:a meta-analysis[J].
Lancet,2007,370(9581):59-67.
[16]LIU Y, SUN L Y, ZHU Z J, et al. Post-transplant lymphoproliferative disorder after paediatric liver transplantation[J]. Int J Clin
Pract,2020,21:e13843.
[17]DIERICKX D,HABERMANN T M. Post-Transplantation Lymphoproliferative Disorders in Adults
[J]. N Engl J Med,
2018,378(6):549-562.
[18]TRAPPE R,OERTEL S,LEBLOND V,et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult
B-cell post-transplant lymphoproliferative disorder (PTLD):the
prospective international multicentre phase 2PTLD-1trial[J].
Lancet Oncol,2012,13(2):196-206.
[19]IGNACAK E,SUŁOWICZ J,GIZA A,et al. Post-transplant lymphoproliferative disorder in a patient after kidney transplant,
5-year follow-up:a case report [J]. Transplant Proc,2020,
52(8):2517-2519.
[20]BREWIN J,MANCAO C,STRAATHOF K,et al. Generation of EBV-specific cytotoxic T cells t
hat are resistant to
calcineurin inhibitors for the treatment of posttransplantation
lymphoproliferative disease[J]. Blood,2009,26,114(23):
4792-803.[21]DANG B N,CH'NG J,RUSSELL M,et al. Treatment of post-transplant lymphoproliferative disorder (PTLD)in a heart
transplant recipient with chimeric antigen receptor T-cell
therapy[J]. Pediatr Transplant,2020,e13861.
[22]ICHEVA V, KAYSER S, WOLFF D, et al. Adoptive transfer of epstein-barr virus (EBV)nuclear antigen 1-specific t cells as
treatment for EBV reactivation and lymphoproliferative disorders
after allogeneic stem-cell transplantation[J]. J Clin Oncol,
2013,31(1):39-48.
[23]PROCKOP S,DOUBROVINA E,SUSER S,et al. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory
EBV-associated lymphoma following transplantation[J]. J Clin
Invest,2020,130(2):733-747.
[24]CHIOU FK,BEATH SV,WILKIE GM,et al. Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative
disorder after solid organ transplantation in children[J]. Pediatr
Transplant,2018,22(2):13133.
[25]ROSSIGNOL J,TERRIOU L,ROBU D,et al.
Radioimmunotherapy (90Y‐Ibritumomab Tiuxetan)for
posttransplant lymphoproliferative disorders after prior exposure to
rituximab[J]. Am J Transplant,2015,15(7):1976-1981.[26]刘静怡,孙丽莹,朱志军,等.
肝移植受者移植后淋巴组织增生性疾病的单中心诊疗经验[J].器官移植,2020,11(6):
711-718.
(收稿日期:2021-01-25)
刘静怡,孙丽莹,朱志军,魏林,刘颖,曲伟,曾志贵,张海明,赵新颜,刘思琦. 儿童肝移植后淋巴组织增生性疾病诊疗分 析[J/CD].实用器官移植电子杂志,2021,9(3):183-189.
·读者·作者·编者·本刊常用的不需要标注中文的缩略语(一)
急性髓系白血病(acute myelogenous leukemia,AML)
qnmlgb
移植后淋巴增殖性疾病(posttransplant lymphoproliferative disorders,PTLD)
巨细胞病毒(cytomegalovirus,CMV)
弥漫性大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)
骨髓增生异常综合征(myelodysplastic syndrome,MDS)
噬血细胞综合征(hemophagocytics syndrome,HPS)
血栓性微血管病(thrombotic microangiopathy,TMA)
过客淋巴细胞综合征(passenger lymphocyte syndrome,PLS)
乳酸脱氢酶(lactic dehydrogenase,LDH)
实体器官移植(solid organ transplantation,SOT)